Fig. 8

Clinical association among the expression of CLDN6, SREBP1, and RAS in patients with BC. A The levels of CLDN6, SREBP1, and HRAS mRNA expression were compared between normal tissues and BC tissues using GSE103512 (normal, 10 and tumor, 65). B Visualization of the low and high expression of CLDN6, SREBP1 and RAS in human BC tissues (n = 50). Scale bar, 200 μm (left) and 20 μm (right). C The distribution of CLDN6 expression levels in patients with BC with and without lymph node involvement. D–F Correlation analysis was conducted on a BC tissue microarray, examining the relationship between CLDN6 and SREBP1 (D), SREBP1 and RAS (E), as well as CLDN6 and RAS (F) (n = 50). G A suggested framework elucidating the regulatory process by which CLDN6 hinders the progression of BC via SREBP1-facilitated RAS palmitoylation. *P < 0.05, **P < 0.01, ***P < 0.001 denoted statistically significant differences